<DOC>
	<DOCNO>NCT02690974</DOCNO>
	<brief_summary>The primary purpose study describe tolerability treatment optimal dose LCZ696 ( 97.2 mg sacubitril / 102.8 mg valsartan bid ) , six ( 6 ) month , patient heart failure reduce ejection fraction ( HFrEF ) Canada . The study also describe overall tolerability , effectiveness safety LCZ696 management HFrEF 12 month treatment , well describe pattern LCZ696 dose titration occur management patient HFrEF .</brief_summary>
	<brief_title>Description Tolerability LCZ696 ( Sacubitril / Valsartan ) Heart Failure With Reduced Ejection Fraction ( HFrEF ) Treated Real Life Setting</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>1 . Written informed consent must obtain assessment perform . 2 . Age ≥ 18 year ≤ 80 year . 3 . Males female . 4 . Diagnosis Heart Failure NYHA class IIIII . 5 . Diagnosis Heart Failure reduce Ejection Fraction ( LVEF &lt; 40 % ) NYHA class II III . 6 . Stable dose ACEI ARB prior enrolment study 7 . Stable dose betablocker prior enrolment study . 8 . Eligible treatment LCZ696 per Canadian product monograph . 9 . Treated outpatient . 10 . Signed informed consent agree participate study . 1 . Symptomatic hypotension and/or SBP &lt; 100 mmHg baseline visit . 2 . Estimated GFR &lt; 30 mL/min/1.73m^2 measure simplified Modification Diet Renal Disease ( MDRD ) formula baseline visit . 3 . Known history angioedema relate previous ACEI ARBs therapy , history hereditary idiopathic angioedema . 4 . Requirement concomitant treatment ACEIs ARBs . 5 . Concurrent participation clinical trial receive investigational drug within 30 day enrollment . 6 . Hypersensitivity active substance , sacubitril valsartan , excipients . 7 . Concomitant use aliskirencontaining drug patient diabetes mellitus ( type 1 type 2 ) moderate severe renal impairment ( GFR &lt; 60ml/min/1.73m^2 ) . 8 . History hypersensitivity study drug drug similar chemical class . 9 . History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past 5 year , regardless whether evidence local recurrence metastasis . 10 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test . 11 . Women childbearing potential , defined woman physiologically capable become pregnant , unless use effective method contraception dose study treatment . Effective contraception method describe protocol . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HFrEF ,</keyword>
	<keyword>ACEi ,</keyword>
	<keyword>ACE inhibitor ,</keyword>
	<keyword>ARBs ,</keyword>
	<keyword>systolic heart failure ,</keyword>
	<keyword>chronic heart failure ,</keyword>
	<keyword>CHF ,</keyword>
	<keyword>reduce EF ,</keyword>
	<keyword>Ejection Fraction</keyword>
</DOC>